Review Article
Development of Immunopathogenesis Strategies to Treat Behçet’s Disease

Osman Köse

Department of Dermatology, School of Medicine, Gülhane Military Medical Academy, Tevfik Saglam Street No. 1, 06018 Ankara, Turkey

Correspondence should be addressed to Osman Köse, drosmankose@yahoo.com

Received 8 August 2011; Accepted 25 January 2012

Academic Editor: Ümit Tursen

Copyright © 2012 Osman Köse. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Behçet disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease. Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel therapeutic modalities. These drugs target specific and nonspecific inhibition of the immun system. These therapies include biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis of Behçet’s diseases and novel treatment modalities will be discussed.

1. Introduction

Behçet disease (BD) is a vasculitis that, characterized by recurrent aphthous stomatitis, genital ulcers, skin lesions, relapsing uveitis, articular, neurologic, urogenital, vascular, intestinal, and pulmonary manifestations [1–3]. BD has been reported worldwide but has a distinct geographic distribution, with highest prevalences in countries such as Turkey, Iran, and Japan which are place on silk road. Although much has been learned during recent years on the pathogenesis and treatment of the disease, the etiology and pathogenesis of BD have not been fully clarified [4, 5]. Symptoms of the disease are considered to be based on the correlation between the genetic intrinsic factors and the triggering extrinsic factors, because more than 60% of BD patients are associated with HLA-B 51. Immune-mediated mechanisms play a major role in the pathogenesis of the disease, and inflammatory mediators are also involved [4–6]. Nowadays, recent investigations have made clear explanations about the pathogenesis of the disease. The hypersensitivity of T lymphocytes to different types of antigens plays a crucial role in the pathogenesis [3–6].

The present paper overviews an update on the immunopathogenesis of BD and also novel treatment based on pathogenesis.

2. Immunopathogenesis of Behçet’s Disease

BD is an inflammatory disorder characterized mainly by mucocutaneous findings and uveitis. However, it can be present with other cutaneous symptoms such as pseudofolliculitis, erythema nodosum, and pyoderma gangrenosum [2–5]. It can be present with articular, neurological, pulmonary, intestinal manifestations other than classical triad. The close relationship between the genetic and triggering external factors is thought to be present in the pathogenesis of BD [3, 4]. The immunopathogenesis of BD is shown in Figure 1. Critical region for BD in the human major histocompatibility complex (MHC) gene could be pinpointed to a 46 kb segment between the MHC class I gene and HLA-B51 gene [5].

2.1. Heat Shock Proteins (HSP). HSP, which essentially scavenge denatured intracellular proteins, are supposed to be induced by microorganisms and mammalian tissues under
a variety of stressful conditions, and they may be involved in the pathogenesis of some autoimmune diseases [5]. The serum levels of IgA antibodies to mycobacterial Hsp-65, which cross react with selected strains of \textit{S. Sanguinis}, are increased significantly. These HSP presented by APCs can directly stimulate \( \alpha \), beta T cells, and \( \gamma\delta \) T cells which play important roles in the oral mucosal immunity as the first defense against microorganisms. Altered expression of Hsp-60 was found in ulcerative lesions of BD and RAS suggesting that HSP-60 has an association with the etiology or chronicity of these inflammatory lesions [7].

2.2. APCs (Antigen Presenting Cells). APC is specialized cell that helps fight off foreign substances that enter the body. Different types of antigens include viruses, bacteria, heat shock protein, and endothelial antigens that stimulate the APC. These cells send out signals to T cells (other immune system cells) when an antigen enters the body [6]. Antigen presentation stimulates T cells to become either “cytotoxic” CD8+ cells or “helper” CD4+ cells. Cytotoxic cells directly attack other cells carrying certain foreign or abnormal molecules on their surfaces. Helper T cells, or Th cells, coordinate immune responses by communicating with other cells. Dysfunction of the APC is responsible for T-cell hypersensitivity. And also this reaction expresses delayed type hypersensitivity mediated by interleukins such as IL-12 and IL-18 in the cutaneous lesions [4].

2.3. Neutrophils. These cells are the main elements of the innate immunity. Meanwhile, cytokines and chemokines secreted from APCs and T cells induce the neutrophil hyperactivation. Hyperactivity of the neutrophils is a major part of the immunological abnormalities observed in BD [5, 6, 8]. Activated neutrophils secrete some cytokines which prime themselves and also stimulate Th1 cells. Th1 lymphocytes have a major role in immunopathogenesis of BD [6, 8].

2.4. \( \gamma\delta \) T Cells. \( \gamma\delta \) T cells, which are important of mucosal immunity have an crucial role. Activity of the BD increases with high level of \( \gamma\delta \) T cells in circulation and mucosal lesions. CD+8 \( \gamma\delta \) T cells rather than CD4+ T cells were activated in vivo in Behçet’s patients [3, 6, 8]. In our study, expression of the \( \gamma\delta \) T cells in oral ulcers from BD patients were studied. It was found heterogeneous expression of the \( \gamma\delta \) T cells throughout the epithelium and in connective tissue around the ulcer base [9].

2.5. Proinflammatory Cytokines. It was claimed that tumor necrosis factor (TNF) \( \alpha \) gene is closely linked to the HLA-B 51 gene, in view of the major role played by this proinflammatory cytokine in BD [3, 6, 8]. An overproduction of proinflammatory cytokines from cellular resources appears to be responsible for the inflammatory reaction in BD, with interferon-\( \gamma \), TNF-\( \alpha \), IL-6, IL-8, and IL-12 being higher in patients with BD. T-cell-produced cytokines, including
interleukin (IL)-2, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-12 and IL-18, are elevated and probably contribute to neutrophil and endothelial cell activation. And also IL-12, and IL-18, which are mainly produced by APCs, regulate the neutrophil function and may play important role in the skewing of immune response [4, 8].

2.6. Th17 Cells. It was reported a marked increase in Th17 cell numbers and a decreased frequency of CD4 (+) forhead box protein 3 positive Treg cells in the peripheral blood of patients with active BD [8–12]. Th17/Th1 ratio was elevated in BD patients with uveitis or folliculitis compared to those without it [11]. Th17 cells regulate inflammation via production of distinct cytokines such as IL-17. There is growing evidence that Th17 cells are pathological in many human autoimmune and inflammatory diseases [8–12]. Th17 cells represent a new subset of Th cells, which mainly produce IL-17A-E, IL-22, and TNF-α. IL-6 and TGF-β induce the differentiation of Th17 cells form naïve T cells. Hamzou et al. found high level of TBX 21 (Th1), RORC (Th17) and Foxp3 (Treg) in neuro-BD. They postulated Th1 and Th17 mRNA expressions involving a possible impairment of Treg cells [13].

2.7. IL-21. Geri et al. demonstrated the presence of the IL-21 and IL-17-A producing T cells within the cerebrospinal fluid, brain parenchyma inflammatory infiltrates, and intracerebral blood vessels form patients with active BD and central nervous system involvement. The stimulation of CD(+) T cells with IL-21 increased Th17 and Th1 differentiation and decreased the frequency of Treg cells. IL-21 represents a promising target for novel therapy in BD [14]. Jiang et al. found strong association of a single-nucleotide polymorphism of IL-23R with BD. The results suggested that IL-23R is predisposing genotypes for BD [15].

2.8. VEGF. In other study, VEGF (vascular endothelial growth factor) was measured in the cerebrospinal fluid in neuro-BD and was found significantly increased. They speculated that VEGF may be associated with the increased percentages of CD4 cell subpopulation [16].

2.9. Vitamin D. Serum vitamin D concentrations and BD activity were investigated. Active BD was associated with lower serum vitamin D levels. These results showed that low levels of vitamin D were associated with a decrease in Treg cells and a skewing of the Th1/Th2 balance towards Th1 [17].

2.10. Histopathology. Histopathogenesis of this disease, characterized by systemic perivasculitis, with presence of early neutrophil infiltration, endothelial cell swelling, and fibrinoid necrosis [1–3]. Prominent neutrophil infiltration is seen in all early mucocutaneous lesions. Recurrent aphthous ulceration, skin pathergy reaction, nodular cutaneous lesion, and also ocular lesion show this type of histopathologic pattern [3, 4].

3. Novel Treatment of Behçet’s Diseases Based on Immunopathogenesis

In general, BD patients have been treated for suppressing the symptoms. Conventional therapeutic approaches suppress the activity of the leucocytes (antinflammatory) and lymphocytes (immunosuppressive) in T-cell-mediated diseases, for the suppression of the immune system. Generally, BD patients have been treated with the antisymptomatic drugs as follows; immunosuppressants such as nonsteroid anti-inflammatory agents, steroids, colchicine, cyclosporine-A. [1, 3, 4]. Meanwhile, the treatment of BD therapy remains still empirical, but nowadays new insights into BD immunopathogenesis have led to novel therapeutic approaches [18–20]. On the other hand, HSP seems to play an important role in the pathogenesis of BD. The probability of a new therapy for BD should be as the immune tolerance utilizing the peptides of HSP.

3.1. Biologic Agents. Clinical and laboratory observations suggested an important role of TNF-mediated process in the pathogenesis of BD [21–25]. During the last ten-year period, 3 licenced TNF antagonists drugs such as infliximab (chimeric anti-TNF-α-amonoclonal antibody), adalimumab (humanized anti-TNF-α-amonoclonal antibody) and etanercept (fusion protein human p75 TNF-α receptor IgG1) are increasingly used off-label for patients with BD.

Off-label use of antitumor necrosis factor (TNF) agents for BD is increasing. It was found 88,12 and 13 primary articles on infliximab, etanercept, and adalimumab, reporting on 325, 37, and 28 patients, respectively [21]. Increased levels of TNF, soluble TNF receptors, and TNF-producing cells were found in the peripheral blood of patients with active disease. Among inflammatory cytokine-related genes, TNF blockade reduced expression of IL-1 receptor type 2, interferon γ receptors, IL-6, IL-6 receptors, and IL-17 receptors [22]. It was found that infliximab is capable of interfering with γδ+T cell function in BD characterized by dysregulated cell-mediated immunity [23]. Overall, the majority of patients treated with either infliximab, etanercept, or adalimumab showed improvement of their mucocutaneous manifestations [21].

3.2. Anti-TNF Agents

3.2.1. Infliximab. Infliximab most frequently has been used in BD [24–31]. The dosing regimen for Infliximab was 5 mg/kg IV at weeks 0, 2, 6, and every 8 weeks thereafter [24] and most of these patients were treated with infliximab; remission of oral ulcers, genital ulcers, erythema nodosum, and other skin lesions were noticed in 91%, 96%, 81%, and 77% of them, respectively. A rapid and dramatic improvement of visual acuity and decrease of ocular inflammation starting 24 hours after infliximab was reported [24, 25]. And also long-term effects of repetitive infliximab infusions had positive results regarding the prevention of ocular relapses and tapering of immunosuppressive therapy [25]. Infliximab was used extensively in entero-Behçet, neuro Behçet, and mucocutaneous BD resistant to conventional therapy [26,
Patients than placebo [32–34]. Using the etanercept for ocular remission for mucocutaneous findings in significantly more once a week. Etanercept was found successful in sustaining neuro-immunology of neuro-Behçet diseases. Therefore inhibition of IL-6 signaling could be a new therapeutic regimen for Neuro-Behçet diseases [41]. Tocilizumab was used in 47 year old female with refractory BD. Excellent results were obtained for 1 year. This experience indicates that tocilizumab may constitute a therapeutic option for refractory BD [42].

3.2.2. Etanercept. Etanercept was administered subcutaneously (SC) in a dose of 25 mg twice a week or 50 mg once a week. Etanercept was found successful in sustaining remission for mucocutaneous findings in significantly more patients than placebo [32–34]. Using the etanercept for ocular involvement was found in small case series. Etanercept was found effective in more than half of patients treated with etanercept [32, 33]. Isolated patients with central nervous system involvement were treated with etanercept with favorable results [32, 34].

3.2.3. Adalimumab. Adalimumab was administered SC as 40 mg every 15 days [21]. Using the etanercept and adalimumab for ocular involvement was found in small case series. Complete remission was achieved in all patients treated with adalimumab. 3 patients with gastrointestinal involvement have been treated successfully with adalimumab [34, 35]. On the other hand, few patients with central nervous system involvement were treated with adalimumab with good results [36]. In large clinical study, a total of 69 patients with BD have been treated with infliximab. But seventeen of these (25%) have been switched to adalimumab for lack or loss of efficacy or infusion reactions. It can be postulated that patients with BD showing a scarce response or adverse events to infliximab may successfully be treated with adalimumab [37].

There is enough published experience to suggest that TNF blockade represents an important therapeutic advancement for patients with severe and resistant, or intolerant, to standard immunosuppressive regimens BD.

3.2.4. Rituximab. Rituximab is a chimeric monoclonal antibody that acts against the specific B cell antigen, CD 20. Rituximab was found effective in retinal vasculitis and ocular manifestations in BD [38, 39]. Twenty patients of with intractable ocular lesions of BD were randomized to a rituximab or cytotoxic drugs such as methotrexate, prednisone, and cyclophosphamide [38]. Rituximab was found effective in ocular lesions of the diseases [38, 39].

3.2.5. Campath 1-H. Campath 1-H is a humanized anti-CD52 antibody. The CD52 antigen is present on lymphocytes and macrophages, but the predominant effect of anti-CD52 antibody therapy (CAMPATH 1-H) is T-cell depletion. Lockwood et al. explored the therapeutic response to lymphocyte depletion with a humanized anti-CD 52 antibody in active BD. This drug will be a potential alternative treatment for refractory BD [40].

3.2.6. Tocilizumab. Tocilizumab is a humanized anti-interleukin 6 receptor antibody. Tocilizumab binds both to soluble and to membrane-bound IL-6 receptor [41, 42]. Evidences showed that IL-6 has a crucial role in the pathogenesis of neuro-Behçet diseases. Therefore inhibition of IL-6 signaling could be a new therapeutic regimen for Neuro-Behçet diseases [41]. Tocilizumab was used in 47 year old female with refractory BD. Excellent results were obtained for 1 year. This experience indicates that tocilizumab may constitute a therapeutic option for refractory BD [42].

3.2.7. Gevokizumab. Gevokizumab (XOMA-052) is an Ig G2 humanized monoclonal antibody against human IL-1β, for the potential treatment of BD. In future, this drug will be candidate for the treatment of uveitis in patients with the vasculitic diseases such as BD [43].

3.2.8. Rilonacept and Canakinumab. Two new orphan medicines, Rilonacept (Regeneron) and Canakinumab (Ilaris), are a human anti-IL-1β monoclonal antibody. Their mode of action are based on the neutralization of IL-1β signaling, resulting in suppression of inflammation in patients with disorders of autoinflammation. [44, 45]. IL-1β is one of the major cytokines implicated in the pathogenesis of many inflammatory-associated diseases. IL-1β is, therefore, becoming a focus for the development of new anti-inflammatory drug products [44]. Reports from clinical trials suggest that two drugs were well tolerated in most patients and no serious adverse effects were observed [45].

3.3. Tolerization Therapy. Heat shock proteins (HSPs) are synthesized when cells are exposed to nonspecific stimuli such as trauma, heat, and infection HSP has played major role in pathogenesis of BD. Tolerance induction has been used for the treatment of autoimmune uveitis [18, 20]. Within HSP-60, the 336–351 sequence has been shown to induce uveitis when administered subcutaneously. Oral administration of the 336–351 peptide linked to recombinant cholera B-toxin B subunit (CTB) was found effective in inhibiting the development of uveitis. There were not observed adverse effects during the therapy. Tolerization could become an appealing therapeutic option because of its lack of side effects and the possibility of the use of other treatment modalities [19, 20].

3.4. Immunoablation. Immunoablation with autologous hematopoietic cell transplantation has shown some effectiveness in the treatment of autoimmune diseases. Myeloablative chemotherapy with immunosuppressive drugs followed by autologous transplantation of T-cell-depleted hematopoietic stem cells was found to be safe and effective in BD [18]. Especially in some cases resistant to immunosuppressive drugs, immunoablations could be alternative treatment modalities to control to BD [20].
3.5. Other Drugs

3.5.1. Rebamipide. Rebamipide can be used for oral aphthous ulcers in BD. This drug inhibits free radicals derived from activated neutrophils and decreases the inhibiting inflammatory cytokine [45, 46]. Matsuda et al. used the rebamipide in a multicenter, double-blind, placebo-controlled study 35 patients with BD were randomized 300 mg/day or placebo for 12–24 weeks. In this study, rebamipide was well tolerated and significantly improved the recurrent aphthous stomatitis [46]. In a recent study, Bang et al. used rebamipide plus colchicine versus colchicine in the treatment to BD-like mice. They found that rebamipide helped to function of colchicine to improve the Herpes simplex virus-induced BD symptoms by inhibiting the expression of NADPH oxidase in a vivo mouse model [47].

3.5.2. Immunosuppressants. Tacrolimus and pimecrolimus are macrolide antiinflammatory drugs with potent immunosuppressive activity [48–51]. Tacrolimus is used for its capacity to inhibit T-cell cytokines, such as IL-2, IL-4, and TNF-α. Oral and topical tacrolimus were used to treat the intestinal and ocular BD [47, 48]. On the other hand, in a clinical trial, topical pimecrolimus cream plus colchicine tablets versus colchicine tablets were used in the treatment of genital ulcers in BD. Pimecrolimus cream shortens the pain duration in genital ulcers [50]. In another clinical study, pimecrolimus versus placebo was used in genital ulcer of BD and also pimecrolimus was found safe and efficient in the treatment of genital ulcers, by accelerating the healing [51].

3.5.3. Mycophenolate Sodium. Mycophenolic acid (MPA) is a potent, selective, and reversible inhibitor of inosine monophosphate dehydrogenase and adenosine deaminase. Enteric-coated mycophenolate sodium (EC-MPS), monosodium salt of MPA, allows delayed release of MPA into the small intestine, and it is associated with less adverse effects [52]. Ten patients received enteric-coated formulation of mycophenolate sodium in a standard dose of 720 mg twice daily for six months. Treatment with EC-MPS leads to significant decrease in BD activity. Side effects were mild and did not lead to discontinuation of therapy [53].

3.5.4. Mycophenolate Mofetil. It was presented that 4 cases with parenchymal neuro-BD, where used immunosuppressive drugs could not be continued to intolerance or inefficacy. These patients benefited well from mycophenolate mofetil. The benefit was sustained during 3–7 years of follow-up [54].

References

[1] S. Hirohata and H. Kikuchi, “Behçet’s disease,” Arthritis Research and Therapy, vol. 5, no. 3, pp. 139–146, 2003.
[2] O. Köse, “Diagnosis and differential diagnosis in Behçet’s disease,” Türkderm Deri Hastalıkları ve Frenki Araş., vol. 43, supplement 2, pp. 87–91, 2009.
[3] I. Krause and A. Weinberger, “Behçet’s disease,” Current Opinion in Rheumatology, vol. 20, no. 1, pp. 82–87, 2008.
[4] F. Kaneko, A. Togashi, S. Saito et al., “Behçet’s disease,” Clinical and Developmental Immunology, vol. 2011, Article ID 681956, 2011.
[5] C. Mendoza-Pinto, M. García-Carrasco, M. Jiménez-Hernández et al., “Etiopathogenesis of Behçet’s disease,” Autoimmunity Reviews, vol. 9, no. 4, pp. 241–245, 2010.
[6] V. D. Kapsimali, M. A. Kanakis, G. A. Vaiopoulos, and P. G. Kaklamani, “Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations,” Clinical Rheumatology, vol. 29, no. 11, pp. 1211–1216, 2010.
[7] E. Deniz, U. Guc, N. Buyukbubani, and A. Gul, “HSP 60 expression in recurrent oral ulcerations of Behçet’s disease,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 110, no. 2, pp. 196–200, 2010.
[8] S. Pay, İ. Şimşek, H. Erdem, and A. Dinc, “Immunopathogenesis of Behçet’s disease with special emphasis on the possible role of antigen presenting cells,” Rheumatology International, vol. 27, no. 5, pp. 417–424, 2007.
[9] O. Köse, J. Stewart, A. Waseem, A. Lalli, and F. Fortune, “Expression of cytokertatins, adhesion and activation molecules in oral ulcers of Behçet’s disease,” Clinical and Experimental Dermatology, vol. 33, no. 1, pp. 62–69, 2008.
[10] H. Direskeneli, H. Fujita, and C. A. Akdis, “Regulation of TH17 and regulatory T cells in patients with Behçet disease,” Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 665–666, 2011.
[11] J. Kim, J. A. Park, E. Y. Lee, Y. I. Lee, Y. W. Song, and E. B. Lee, “Imbalance of Th17 to Th1 cells in Behçet’s disease,” Clinical and Experimental Rheumatology, vol. 28, no. 4, supplement 60, pp. S16–S19, 2010.
[12] K. Hamzaouï, “Th17 cells In Behçet’s disease: a new immunoregulatory axis,” Clinical and Experimental Rheumatology, vol. 29, no. 4, supplement 67, pp. S71–S76, 2011.
[13] K. Hamzaouï, A. Borhani Haghighi, I. B. Ghorbel, and H. Houman, “RORC and Foxp3 axis in cerebrospinal fluid of patients with Neuro-Behçet’s Disease,” Journal of Neuroimmunology, vol. 233, no. 1–2, pp. 249–253, 2011.
[14] G. Geri, B. Terrier, M. Rosenzweig et al., “Critical role of IL-21 in modulating T H17 and regulatory T cells in Behçet disease,” Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 655–664, 2011.
[15] Z. Jiang, P. Yang, S. Hou et al., “IL-23R gene confers susceptibility to Behçet’s disease in a Chinese Han population,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1325–1328, 2010.
[16] K. Hamzaouï, K. Ayed, M. Hamza, and A. Hamzaouï, “VGEF and mRNA VEGF expression in CSF from Behçet’s disease with neurological involvement,” Journal of Neuroimmunology, vol. 213, no. 1–2, pp. 148–153, 2009.
[17] K. Hamzaouï, I. B. DhiFAILAH, E. KARRAY, F. H. SASSI, and A. HAMZAOUÏ, “Vitamin D modulates peripheral immunity in patients with Behçet’s disease,” Clinical and Experimental Rheumatology, vol. 28, no. 4, supplement 60, pp. 550–557, 2010.
[18] I. Alexoudi, V. Kapsimali, A. Vaiopoulos, M. Kanakis, and G. Vaiopoulos, “Evaluation of current therapeutic strategies in Behçet’s disease,” Clinical Rheumatology, vol. 30, no. 2, pp. 157–163, 2011.
[19] N. Pipitone, I. Olivieri, F. Cantini, G. Triolo, and C. Salvarani, “New approaches in the treatment of Adamantiades-Behçet’s disease,” Current Opinion in Rheumatology, vol. 18, no. 1, pp. 3–9, 2006.
[21] A. Arida, K. Fragiadaki, E. Giavri, and P. Sfikakis, “Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients,” Seminars in Arthritis and Rheumatism, vol. 41, no. 1, pp. 61–70, 2011.

[22] H. Keino, T. Watanabe, W. Taki, and A. A. Okada, “Effect of infliximab on gene expression profiling in Behçet’s disease,” Investigative Ophthalmology & Visual Science, vol. 52, no. 10, pp. 7681–7686, 2011.

[23] A. Accardo-Palumbo, A. R. Giardina, F. Ciccia et al., “Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet’s disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity,” Arthritis Research and Therapy, vol. 12, no. 3, article R109, 2010.

[24] N. R. Benitał, L. Sobrin, and G. N. Papaliodis, “The use of biologic agents in the treatment of ocular manifestations of Behçet’s disease,” Seminars in Ophthalmology, vol. 26, no. 4-5, pp. 295–303, 2011.

[25] M. Accorinti, M. P. Pirraglia, M. P. Paroli, R. Priori, F. Conti, and P. Pivetti-Pezzi, “Infliximab treatment for ocular and extracocular manifestations of Behçet’s disease,” Japanese Journal of Ophthalmology, vol. 51, no. 3, pp. 191–196, 2007.

[26] N. E. Aikawa, C. Gonçalves, C. A.A. Silva, C. Gonçalves, E. Bonfá, and J. E. De Carvalho, “Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet’s disease,” Rheumatology International, vol. 31, no. 8, pp. 1097–1099, 2011.

[27] N. Markomichelakis, E. Delicha, S. Masselos, K. Fragiadaki, P. Kaklamanis, and P. P. Sfikakis, “A single infliximab injection vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study,” Rheumatology, vol. 50, no. 3, Article ID keq366, pp. 593–597, 2011.

[28] A. Borhani Haghighi, A. Safari, M. A. Nazarinia, Z. Habiba-gahi, and S. Shavaneedeh, “Infliximab for patients with neuro-Behçet’s disease: case series and literature review,” Clinical Rheumatology, vol. 30, no. 7, pp. 1007–1012, 2011.

[29] S. Iwata, K. Saito, K. Yamaoka et al., “Effects of anti-TNF-α antibody infliximab in refractory entero-Behçet’s disease,” Rheumatology, 48, no. 8, pp. 1012–1013, 2009.

[30] G. Almoznino and E. Ben-Chetrit, “Infliximab for the treatment of resistant oral ulcers in Behçet’s disease: a case report and review of the literature,” Clinical and Experimental Rheumatology, vol. 25, no. 4, supplement 45, pp. S–99, 2007.

[31] S. Iwata, K. Saito, K. Yamaoka et al., “Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease,” Modern Rheumatology, vol. 21, no. 2, pp. 184–191, 2011.

[32] L. Cantarini, I. Tinazzi, P. Caramaschi, F. Bellisai, A. Brogna, and M. Galeazzi, “Safety and efficacy of etanercept in children with juvenile-onset Behçet’s disease,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 551–555, 2009.

[33] V. Curigliano, M. Giovinale, C. Fonnesu et al., “Efficacy of etanercept in the treatment of a patient with Behçet’s disease,” Clinical Rheumatology, vol. 27, no. 7, pp. 933–936, 2008.

[34] M. F. Zhang, C. Zhao, X. Wen, H. Du, and Y. Zhao, “The short-term efficacy and safety treatment study of recurrent uveitis in Behçet disease with etanercept,” Chinese Journal of Ophthalmology, vol. 46, no. 2, pp. 145–150, 2010.

[35] A. Bawazer, L. H. Raffa, and Nizamuddin, “Clinical experience with adalimumab in the treatment of ocular Behçet disease,” Ocular Immunology and Inflammation, vol. 18, no. 3, pp. 226–232, 2010.

[36] C. De Cassan, B. De Vroe, C. Dussault, E. Hachulla, S. Buche, and J. F. Colombel, “Successful treatment with adalimumab in a familial case of gastrointestinal Behçet’s disease,” Journal of Crohn’s and Colitis, vol. 5, no. 4, pp. 364–368, 2011.

[37] I. Olivieri, P. Leccese, S. D’Angelo et al., “Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab,” Clinical and Experimental Rheumatology, vol. 29, no. 4, supplement 67, pp. S54–S57, 2011.

[38] F. Davatchi, H. Shams, M. Rezaipoor et al., “Rituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study),” International Journal of Rheumatic Diseases, vol. 13, no. 3, pp. 246–252, 2010.

[39] S. Sadreddini, H. Noshad, M. Moleaeefard, and R. Noshad, “Treatment of retinal vasculitis in Behçet’s disease with rituximab,” Modern Rheumatology, vol. 18, no. 3, pp. 306–308, 2008.

[40] C. M. Lockwood, G. Hale, H. Waldman, and D. R. W. Jayne, “Remission induction in Behçet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H,” Rheumatology, vol. 42, no. 12, pp. 1539–1544, 2003.

[41] A. Borhani Haghighi and A. Safari, “Tofacitinib may be a potential addition to our weapons against neuro-Behçet’s disease,” Medical Hypotheses, vol. 71, no. 1, pp. 156–157, 2008.

[42] T. Hirano, N. Ohguro, S. Hohki et al., “A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab,” Modern Rheumatology. In press.

[43] J. Geiler and M. F. McDermott, “Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease,” Current Opinion in Molecular Therapeutics, vol. 12, no. 6, pp. 755–769, 2010.

[44] E. A. Dubois, R. Riissmann, and A. F. Cohen, “Rilonacept and canakinumab,” British Journal of Clinical Pharmacology, vol. 71, no. 5, pp. 639–641, 2011.

[45] E. Dhimolea, “Canakinumab,” MAbs, vol. 2, no. 1, pp. 3–13, 2010.

[46] T. Matsuda, S. Ohno, S. Hirohata et al., “Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study,” Drugs in R and D, vol. 4, no. 1, pp. 19–28, 2003.

[47] D. Bang, B. Choi, H. J. Kwon, E. S. Lee, S. Lee, and S. Sohn, “Rebamipide affects the efficiency of colchicine for the herpes simplex virus-induced inflammation in a Behçet’s disease mouse model,” European Journal of Pharmacology, vol. 598, no. 1–3, pp. 112–117, 2008.

[48] K. Matsumura, H. Nakase, and T. Chiba, “Efficacy of oral tacrolimus on intestinal Behçet’s disease,” Inflammatory Bowel Diseases, vol. 16, no. 2, pp. 188–189, 2010.

[49] F. N. Yağlındaş, F. Batioglu, and Ö. Ozdemir, “Penetration of topicaly applied tacrolimus into the aqueous humor in Behçet’s disease,” Annales de Ophthalmologie, vol. 39, no. 1, pp. 15–17, 2007.

[50] O. Köse, A. Dinç, and I. Şimşek, “Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet’s disease,” Dermatology, 218, no. 2, pp. 140–143, 2009.

[51] C. Chams-Davatchi, B. Barikbin, F. Shahram et al., “Pimecrolimus versus placebo in genital aphthous ulcers of Behçet’s disease: a randomized double-blind controlled trial,” International Journal of Rheumatic Diseases, vol. 13, no. 3, pp. 253–258, 2010.

[52] J. H. Kappen, P. B. F. Mensink, W. Lesterhuis et al., “Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet’s disease, evaluated with enteroscopy,” American Journal of Gastroenterology, vol. 103, no. 12, pp. 3213–3214, 2008.
[53] O. Köse, I. Şimşek, and S. Pay, “Mycophenolate sodium in the treatment of mucocutaneous Behçet’s diseases,” International Journal of Dermatology, vol. 50, no. 7, pp. 895–896, 2011.

[54] E. Shugaiv, E. Tüzün, M. Mutlu, A. Kiyat-Atamer, M. Kurtuncu, and G. Akman-Demir, “Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet’s disease with parenchymal involvement: presentation of four cases,” Clinical and Experimental Rheumatology, vol. 29, no. 4, supplement 67, pp. S64–S67, 2011.